Abbisko Cayman Limited’s CEO Increases Stake Amid Share Buyback Plan

Abbisko Cayman Limited ( (HK:2256) ) has shared an announcement.

Abbisko Cayman Limited announced an increase in shareholding by its founder and CEO, Dr. Xu Yao-Chang, who purchased 17,000 ordinary shares, bringing his total shareholding to approximately 11.77% of the company. This move reflects Dr. Xu’s confidence in the company’s growth prospects. Additionally, the company has been executing a share repurchase plan, buying back 8,695,000 shares to date, which the board believes will enhance shareholder value as the current trading price undervalues the company’s intrinsic worth.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Cayman Limited is a company incorporated in the Cayman Islands, primarily engaged in the pharmaceutical industry. The company focuses on the development of innovative therapies and has a market presence in Hong Kong, where its shares are traded on the stock exchange.

Average Trading Volume: 5,582,617

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.07B

Learn more about 2256 stock on TipRanks’ Stock Analysis page.